



EPI benefits versus COVID–19 risks

HepB3 / EPI suspension period: 6 months / vaccine impact: lifetime




Hib3 / EPI suspension period: 6 months / vaccine impact: lifetime




MCV1 / EPI suspension period: 6 months / vaccine impact: lifetime


The map displays the distribution of the elderly population across the African continent. Darker shades of blue indicate higher percentages of the population aged 65 and over, while lighter shades indicate lower percentages. The map shows that countries in North Africa, such as Egypt, Libya, and Algeria, have the highest percentages of the elderly population, indicated by the darkest blue shading. In contrast, countries in West and Central Africa, such as Nigeria, DRC, and Ethiopia, have lower percentages, indicated by lighter blue shading. The map also shows that some countries, like Mauritius and Madagascar, have very low percentages of the elderly population, indicated by the lightest blue shading.



MCV2 / EPI suspension period: 6 months / vaccine impact: lifetime




PCV3 / EPI suspension period: 6 months / vaccine impact: lifetime




EPI benefits versus COVID–19 risks

RCV1 / EPI suspension period: 6 months / vaccine impact: lifetime




benefit–risk ratio



EPI benefits versus COVID–19 risks

RotaC / EPI suspension period: 6 months / vaccine impact: lifetime




benefit–risk ratio




50
40
30
20
10

EPI benefits versus COVID–19 risks

YFV / EPI suspension period: 6 months / vaccine impact: lifetime



benefit-risk ratio



EPI benefits versus COVID–19 risks

MenA / EPI suspension period: 6 months / vaccine impact: lifetime




benefit–risk ratio



25
20
15
10
5


EPI benefits versus COVID–19 risks

HPVfem / EPI suspension period: 6 months / vaccine impact: lifetime




EPI benefits versus COVID–19 risks


HepB3, Hib3, PCV3, RotaC / EPI suspension period: 6 months / vaccine impact: lifetime



benefit–risk ratio



MCV1, RCV1, MenA, YFV / EPI suspension period: 6 months / vaccine impact: lifetime



EPI benefits versus COVID–19 risks

HepB3, Hib3, PCV3, RotaC, MCV1, RCV1, MenA, YFV, MCV2 / EPI suspension period: 6 months / vaccine impact: lifetime

